Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar012024	Fate Therapeutics to Present at Upcoming March Investor Conferences SAN DIEGO , March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryMar032023	Fate Therapeutics to Present at Upcoming March Investor Conferences SAN DIEGO , March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryMar022022	Fate Therapeutics to Present at Upcoming March Investor Conferences SAN DIEGO , March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company Read All »	View HTML
Toggle SummaryMay062022	Fate Therapeutics to Present at Upcoming May Investor Conferences SAN DIEGO , May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All »	View HTML
Toggle SummaryAug312023	Fate Therapeutics to Present at Upcoming September Investor Conferences SAN DIEGO , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryOct022013	Fate Therapeutics to Present at World Muscle Society Congress SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that its Senior Vice President, Early Program Development, Dr. Read All »	View HTML Fate Therapeutics to Present at World Muscle Society Congress 13.8 KB
Toggle SummaryNov032022	Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell Lymphoma Preclinical Data of FT555 GPRC5D-targeted CAR NK Cell Collaboration Candidate for Multiple Read All »	View HTML
Toggle SummaryOct052022	Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting SAN DIEGO , Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinical data Read All »	View HTML
Toggle SummaryJul082009	Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway La Jolla, CA and Barcelona – Fate Therapeutics, Inc. announced today the presentation of data from its research on small molecule modulators of the Wnt pathway for Read All »	View HTML Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway 12.9 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. Read All »	View HTML Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting 61.9 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.